Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa open-label dose-escalation study of monthly semaglutide depot in adults with type 2 diabetes mellitus
MOH_2024-05-21_011934Phase 2Recruiting
- Sponsor
- Mapi Pharma
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Mapi Pharma. Primary endpoints: Safety, Tolerability and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2024-05-21_011934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-21_011934.